S&P 500   4,524.44 (-0.56%)
DOW   35,537.79 (-0.18%)
QQQ   373.48 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.61 (-0.69%)
FB   322.42 (-5.69%)
GOOGL   2,744.06 (-3.30%)
TSLA   899.39 (+0.60%)
AMZN   3,353.27 (-2.38%)
NVDA   227.15 (+0.10%)
BABA   178.23 (+0.46%)
NIO   39.14 (-2.08%)
CGC   13.38 (-4.70%)
GE   103.92 (+0.75%)
AMD   118.98 (-0.29%)
MU   67.29 (-1.97%)
T   25.58 (-0.70%)
F   16.37 (-1.09%)
ACB   7.11 (-3.53%)
DIS   169.04 (-1.34%)
PFE   42.76 (-0.23%)
BA   213.63 (-0.33%)
AMC   36.55 (-6.86%)
S&P 500   4,524.44 (-0.56%)
DOW   35,537.79 (-0.18%)
QQQ   373.48 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.61 (-0.69%)
FB   322.42 (-5.69%)
GOOGL   2,744.06 (-3.30%)
TSLA   899.39 (+0.60%)
AMZN   3,353.27 (-2.38%)
NVDA   227.15 (+0.10%)
BABA   178.23 (+0.46%)
NIO   39.14 (-2.08%)
CGC   13.38 (-4.70%)
GE   103.92 (+0.75%)
AMD   118.98 (-0.29%)
MU   67.29 (-1.97%)
T   25.58 (-0.70%)
F   16.37 (-1.09%)
ACB   7.11 (-3.53%)
DIS   169.04 (-1.34%)
PFE   42.76 (-0.23%)
BA   213.63 (-0.33%)
AMC   36.55 (-6.86%)
S&P 500   4,524.44 (-0.56%)
DOW   35,537.79 (-0.18%)
QQQ   373.48 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.61 (-0.69%)
FB   322.42 (-5.69%)
GOOGL   2,744.06 (-3.30%)
TSLA   899.39 (+0.60%)
AMZN   3,353.27 (-2.38%)
NVDA   227.15 (+0.10%)
BABA   178.23 (+0.46%)
NIO   39.14 (-2.08%)
CGC   13.38 (-4.70%)
GE   103.92 (+0.75%)
AMD   118.98 (-0.29%)
MU   67.29 (-1.97%)
T   25.58 (-0.70%)
F   16.37 (-1.09%)
ACB   7.11 (-3.53%)
DIS   169.04 (-1.34%)
PFE   42.76 (-0.23%)
BA   213.63 (-0.33%)
AMC   36.55 (-6.86%)
S&P 500   4,524.44 (-0.56%)
DOW   35,537.79 (-0.18%)
QQQ   373.48 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.61 (-0.69%)
FB   322.42 (-5.69%)
GOOGL   2,744.06 (-3.30%)
TSLA   899.39 (+0.60%)
AMZN   3,353.27 (-2.38%)
NVDA   227.15 (+0.10%)
BABA   178.23 (+0.46%)
NIO   39.14 (-2.08%)
CGC   13.38 (-4.70%)
GE   103.92 (+0.75%)
AMD   118.98 (-0.29%)
MU   67.29 (-1.97%)
T   25.58 (-0.70%)
F   16.37 (-1.09%)
ACB   7.11 (-3.53%)
DIS   169.04 (-1.34%)
PFE   42.76 (-0.23%)
BA   213.63 (-0.33%)
AMC   36.55 (-6.86%)
NASDAQ:ETTX

Entasis Therapeutics Stock Forecast, Price & News

$2.63
-0.17 (-6.07 %)
(As of 10/22/2021 11:34 AM ET)
Add
Compare
Today's Range
$2.63
$2.69
50-Day Range
$2.29
$3.77
52-Week Range
$1.58
$3.88
Volume2,568 shs
Average Volume585,032 shs
Market Capitalization$124.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
30 days | 90 days | 365 days | Advanced Chart
Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Entasis Therapeutics logo

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETTX
Employees
47
Year Founded
N/A

Sales & Book Value

Annual Sales
$7 million
Book Value
$1.47 per share

Profitability

Net Income
$-50.50 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$124.43 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

688th out of 1,358 stocks

Pharmaceutical Preparations Industry

330th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

Is Entasis Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Entasis Therapeutics stock.
View analyst ratings for Entasis Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Entasis Therapeutics?

Wall Street analysts have given Entasis Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Entasis Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Entasis Therapeutics
.

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.05.
View Entasis Therapeutics' earnings history
.

How has Entasis Therapeutics' stock price been impacted by COVID-19?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETTX shares have decreased by 36.3% and is now trading at $2.63.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ETTX?

3 Wall Street analysts have issued 1-year price objectives for Entasis Therapeutics' shares. Their forecasts range from $6.00 to $7.00. On average, they expect Entasis Therapeutics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 147.1% from the stock's current price.
View analysts' price targets for Entasis Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Manoussos Perros, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Mike Gutch, Secretary, Chief Financial & Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • David Altarac, Chief Medical Officer
  • John Mueller, Chief Development Officer

What other stocks do shareholders of Entasis Therapeutics own?

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.63.

How much money does Entasis Therapeutics make?

Entasis Therapeutics has a market capitalization of $124.43 million and generates $7 million in revenue each year. The company earns $-50.50 million in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Entasis Therapeutics have?

Entasis Therapeutics employs 47 workers across the globe.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is www.entasistx.com.

Where are Entasis Therapeutics' headquarters?

Entasis Therapeutics is headquartered at 35 GATEHOUSE DRIVE, WALTHAM MA, 02451.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at (781) 810-0120 or via email at [email protected].


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.